Alirocumab (CAS RN 1245916-14-6) is a fully human monoclonal antibody that consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a fully human kappa light chain. A single N-linked glycosylation site is located in each heavy chain within the CH2 domain of the fragment crystallizable (Fc) constant region of the molecule. The variable domains of the heavy and light chains combine to form the proprotein convertase subtilisin kexin type 9 (PCSK9) binding site within the antibody. Alirocumab has an approximate molecular weight of 146 kDa.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Alirocumab, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.